AMARIN CORPORATION PLC (AMRN)
New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
📉 **NEGATIVE** • Low confidence analysis (49%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (21%) **Content type:** Clinical